{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T01:35:58Z","timestamp":1787016958212,"version":"build-2736575974"},"reference-count":58,"publisher":"BMJ","issue":"3","license":[{"start":{"date-parts":[[2021,3,18]],"date-time":"2021-03-18T00:00:00Z","timestamp":1616025600000},"content-version":"unspecified","delay-in-days":17,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2020,12,26]]},"published-print":{"date-parts":[[2021,3]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Osteosarcoma is the most common malignant solid tumor that affects bones, however, survival rates of patients with relapsed osteosarcoma have not improved in the last 30 years. Oncolytic virotherapy, which uses viruses designed to selectively replicate in cancer cells, has emerged as a promising treatment for solid tumors. Our group uses mesenchymal stem cells (MSCs) to transport oncolytic adenoviruses (OAds) to the tumor site, a therapeutic strategy called Celyvir. This treatment has been already applied in human patients, canine patients and different mouse models. In parallel, previous results have probed that administration of granulocyte-colony stimulating factor (G-CSF) increased immune infiltration in tumors. We then hypothesized that the mobilization of immune cells by G-CSF may increase the antitumor efficacy of Celyvir treatment by increasing the immune infiltration into the tumors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this study, we use a murine version of Celyvir consisting in murine MSCs carrying the murine OAd dlE102\u2014here called OAd-MSCs\u2014in an immunocompetent model of osteosarcoma. We tested the antitumoral efficacy of the combination of OAd-MSCs plus G-CSF.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Our results show that treatment with OAd-MSCs or the union of OAd-MSCs with G-CSF (Combination) significantly reduced tumor growth of osteosarcoma in vivo. Moreover, treated tumors presented higher tumor infiltration of immune cells\u2014especially tumor-infiltrating lymphocytes\u2014and reduced T cell exhaustion, which seems to be enhanced in tumors treated with the Combination. The comparison of our results to those obtained from a cohort of pediatric osteosarcoma patients showed that the virotherapy induces immunological changes similar to those observed in patients with good prognosis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The results open the possibility of using cellular virotherapy for the treatment of bone cancers. Indeed, its combination with G-CSF may be considered for the improvement of the therapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/jitc-2020-001703","type":"journal-article","created":{"date-parts":[[2021,3,18]],"date-time":"2021-03-18T13:06:43Z","timestamp":1616072803000},"page":"e001703","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":34,"title":["Combination immunotherapy using G-CSF and oncolytic virotherapy reduces tumor growth in osteosarcoma"],"prefix":"10.1136","volume":"9","clinical-trial-number":[{"clinical-trial-number":"nct01844661","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00931931","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00503295","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01169584","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4532-7667","authenticated-orcid":false,"given":"Alvaro","family":"Morales-Molina","sequence":"first","affiliation":[{"name":"Cellular Biotechnology Unit, Instituto de Salud Carlos III, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Gambera","sequence":"additional","affiliation":[{"name":"Cellular Biotechnology Unit, Instituto de Salud Carlos III, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Leo","sequence":"additional","affiliation":[{"name":"Department of Biomedical, Experimental and Clinical Sciences, University of Florence, Firenze, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7604-1640","authenticated-orcid":false,"given":"Javier","family":"Garc\u00eda-Castro","sequence":"additional","affiliation":[{"name":"Cellular Biotechnology Unit, Instituto de Salud Carlos III, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2021,3,18]]},"reference":[{"key":"2025100308202749000_9.3.e001703.1","doi-asserted-by":"publisher","DOI":"10.1007\/s10552-015-0607-3"},{"key":"2025100308202749000_9.3.e001703.2","first-page":"iii113","article-title":"Bone sarcomas: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"25 Suppl 3","year":"2014","journal-title":"Ann Oncol"},{"key":"2025100308202749000_9.3.e001703.3","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.201911131","article-title":"Sarcoma treatment in the era of molecular medicine","volume":"12","author":"Gr\u00fcnewald","year":"2020","journal-title":"EMBO Mol Med"},{"key":"2025100308202749000_9.3.e001703.4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2011\/548151","article-title":"Using epidemiology and genomics to understand osteosarcoma etiology","volume":"2011","author":"Savage","year":"2011","journal-title":"Sarcoma"},{"key":"2025100308202749000_9.3.e001703.5","first-page":"59","article-title":"Descriptive epidemiology of malignant primary osteosarcoma using population-based registries, United States, 1999-2008","volume":"40","author":"Duong","year":"2013","journal-title":"J Registry Manag"},{"key":"2025100308202749000_9.3.e001703.6","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3838"},{"key":"2025100308202749000_9.3.e001703.7","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.jbo.2016.12.001","article-title":"Oncolytic adenoviruses as a therapeutic approach for osteosarcoma: a new hope","volume":"9","author":"Garcia-Moure","year":"2017","journal-title":"J Bone Oncol"},{"key":"2025100308202749000_9.3.e001703.8","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-06-4675"},{"key":"2025100308202749000_9.3.e001703.9","doi-asserted-by":"publisher","DOI":"10.1038\/sj.mt.6300239"},{"key":"2025100308202749000_9.3.e001703.10","doi-asserted-by":"publisher","DOI":"10.1002\/stem.187"},{"key":"2025100308202749000_9.3.e001703.11","doi-asserted-by":"crossref","first-page":"149","DOI":"10.2147\/OV.S66010","article-title":"Patient-Derived mesenchymal stem cells as delivery vehicles for oncolytic virotherapy: novel state-of-the-art technology","volume":"4","author":"Ram\u00edrez","year":"2015","journal-title":"Oncolytic Virother"},{"key":"2025100308202749000_9.3.e001703.12","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2020.172991","article-title":"Mesenchymal stem cells as carriers for systemic delivery of oncolytic viruses","volume":"874","author":"Hadry\u015b","year":"2020","journal-title":"Eur J Pharmacol"},{"key":"2025100308202749000_9.3.e001703.13","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-57240-x","article-title":"Mesenchymal stem cells used as carrier cells of oncolytic adenovirus results in enhanced oncolytic virotherapy","volume":"10","author":"Mahasa","year":"2020","journal-title":"Sci Rep"},{"key":"2025100308202749000_9.3.e001703.14","doi-asserted-by":"publisher","DOI":"10.1038\/cgt.2010.4"},{"key":"2025100308202749000_9.3.e001703.15","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.canlet.2015.11.036","article-title":"Influence of carrier cells on the clinical outcome of children with neuroblastoma treated with high dose of oncolytic adenovirus delivered in mesenchymal stem cells","volume":"371","author":"Melen","year":"2016","journal-title":"Cancer Lett"},{"key":"2025100308202749000_9.3.e001703.16","doi-asserted-by":"crossref","first-page":"10543","DOI":"10.1200\/JCO.2018.36.15_suppl.10543","article-title":"First-in-child trial of celyvir (autologous mesenchymal stem cells carrying the oncolytic virus ICOVIR-5) in patients with relapsed and refractory pediatric solid tumors","volume":"36","author":"Ramirez","year":"2018","journal-title":"Journal of Clinical Oncology"},{"key":"2025100308202749000_9.3.e001703.17","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/j.ymthe.2020.01.019","article-title":"First-in-human, first-in-child trial of autologous MscS carrying the oncolytic virus Icovir-5 in patients with advanced tumors","volume":"28","author":"Ruano","year":"2020","journal-title":"Mol Ther"},{"key":"2025100308202749000_9.3.e001703.18","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2014.7"},{"key":"2025100308202749000_9.3.e001703.19","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-17-3754"},{"key":"2025100308202749000_9.3.e001703.20","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.2253"},{"key":"2025100308202749000_9.3.e001703.21","doi-asserted-by":"crossref","DOI":"10.3390\/v9100301","article-title":"Preclinical testing of an oncolytic parvovirus: standard Protoparvovirus H-1PV efficiently induces osteosarcoma cell lysis in vitro","volume":"9","author":"Geiss","year":"2017","journal-title":"Viruses"},{"key":"2025100308202749000_9.3.e001703.22","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12051070","article-title":"Novel oncolytic virus armed with cancer suicide gene and normal vasculogenic gene for improved anti-tumor activity","volume":"12","author":"Jeong","year":"2020","journal-title":"Cancers"},{"key":"2025100308202749000_9.3.e001703.23","doi-asserted-by":"crossref","first-page":"45415","DOI":"10.18632\/oncotarget.17557","article-title":"Mesenchymal stem cell carriers enhance antitumor efficacy of oncolytic adenoviruses in an immunocompetent mouse model","volume":"8","author":"Rinc\u00f3n","year":"2017","journal-title":"Oncotarget"},{"key":"2025100308202749000_9.3.e001703.24","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1007\/s00262-018-2220-2","article-title":"Antitumor virotherapy using syngeneic or allogeneic mesenchymal stem cell carriers induces systemic immune response and intratumoral leukocyte infiltration in mice","volume":"67","author":"Morales-Molina","year":"2018","journal-title":"Cancer Immunol Immunother"},{"key":"2025100308202749000_9.3.e001703.25","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12071920","article-title":"Cellular Virotherapy Increases Tumor-Infiltrating Lymphocytes (TIL) and Decreases their PD-1+ Subsets in Mouse Immunocompetent Models","volume":"12","author":"Morales-Molina","year":"2020","journal-title":"Cancers"},{"key":"2025100308202749000_9.3.e001703.26","doi-asserted-by":"crossref","first-page":"347","DOI":"10.18632\/oncotarget.27401","article-title":"Systemic oncolytic adenovirus delivered in mesenchymal carrier cells modulate tumor infiltrating immune cells and tumor microenvironment in mice with neuroblastoma","volume":"11","author":"Franco-Luz\u00f3n","year":"2020","journal-title":"Oncotarget"},{"key":"2025100308202749000_9.3.e001703.27","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.02561-08"},{"key":"2025100308202749000_9.3.e001703.28","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2014.03.003"},{"key":"2025100308202749000_9.3.e001703.29","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1093\/annonc\/mdy311","article-title":"Overall survival and risk of second malignancies with cancer chemotherapy and G-CSF support","volume":"29","author":"Lyman","year":"2018","journal-title":"Ann Oncol"},{"key":"2025100308202749000_9.3.e001703.30","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djk015"},{"key":"2025100308202749000_9.3.e001703.31","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdt226"},{"key":"2025100308202749000_9.3.e001703.32","unstructured":"Espinoza ML . Movilizaci\u00f3n de linfocitos infiltrantes de tumor a sangre perif\u00e9rica en un modelo murino de neuroblastoma. An\u00e1lisis inmunofenot\u00edpico, clonal Y funcional. Madrid: Universidad Aut\u00f3noma de Madrid, 2020."},{"key":"2025100308202749000_9.3.e001703.33","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2016.00353","article-title":"T-Cell-based immunotherapy for osteosarcoma: challenges and opportunities","volume":"7","author":"Wang","year":"2016","journal-title":"Front Immunol"},{"key":"2025100308202749000_9.3.e001703.34","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.immuni.2018.06.006","article-title":"Tumor cell-intrinsic factors underlie heterogeneity of immune cell infiltration and response to immunotherapy","volume":"49","author":"Li","year":"2018","journal-title":"Immunity"},{"key":"2025100308202749000_9.3.e001703.35","doi-asserted-by":"crossref","first-page":"201","DOI":"10.2217\/imt-2018-0111","article-title":"Enhancing tumor T cell infiltration to enable cancer immunotherapy","volume":"11","author":"Zhang","year":"2019","journal-title":"Immunotherapy"},{"key":"2025100308202749000_9.3.e001703.36","doi-asserted-by":"publisher","DOI":"10.1111\/j.1432-0436.1988.tb00090.x"},{"key":"2025100308202749000_9.3.e001703.37","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1002\/stem.1647","article-title":"Bone environment is essential for osteosarcoma development from transformed mesenchymal stem cells","volume":"32","author":"Rubio","year":"2014","journal-title":"Stem Cells"},{"key":"2025100308202749000_9.3.e001703.38","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-018-06401-z","article-title":"Clonal dynamics in osteosarcoma defined by RGB marking","volume":"9","author":"Gambera","year":"2018","journal-title":"Nat Commun"},{"key":"2025100308202749000_9.3.e001703.39","doi-asserted-by":"publisher","DOI":"10.1006\/viro.1996.0520"},{"key":"2025100308202749000_9.3.e001703.40","doi-asserted-by":"crossref","first-page":"1902880","DOI":"10.1002\/advs.201902880","article-title":"ImmuCellAI: a unique method for comprehensive T-cell subsets abundance prediction and its application in cancer immunotherapy","volume":"7","author":"Miao","year":"2020","journal-title":"Adv Sci"},{"key":"2025100308202749000_9.3.e001703.41","doi-asserted-by":"crossref","first-page":"919","DOI":"10.12688\/f1000research.11830.1","article-title":"CASAS: cancer survival analysis suite, a web based application","volume":"6","author":"Rupji","year":"2017","journal-title":"F1000Res"},{"key":"2025100308202749000_9.3.e001703.42","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-0477"},{"key":"2025100308202749000_9.3.e001703.43","doi-asserted-by":"crossref","DOI":"10.1038\/srep39862","article-title":"Prognostic value of inflammation-based scores in patients with osteosarcoma","volume":"6","author":"Liu","year":"2016","journal-title":"Sci Rep"},{"key":"2025100308202749000_9.3.e001703.44","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellimm.2017.10.011","article-title":"The contribution of immune infiltrates and the local microenvironment in the pathogenesis of osteosarcoma","volume":"343","author":"Heymann","year":"2019","journal-title":"Cell Immunol"},{"key":"2025100308202749000_9.3.e001703.45","doi-asserted-by":"publisher","DOI":"10.1186\/1479-5876-10-205"},{"key":"2025100308202749000_9.3.e001703.46","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-020-14646-w","article-title":"Immuno-genomic landscape of osteosarcoma","volume":"11","author":"Wu","year":"2020","journal-title":"Nat Commun"},{"key":"2025100308202749000_9.3.e001703.47","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2017.1331193","article-title":"CD163-positive tumor-associated macrophages and CD8-positive cytotoxic lymphocytes are powerful diagnostic markers for the therapeutic stratification of osteosarcoma patients: an immunohistochemical analysis of the biopsies fromthe French OS2006 phase 3 trial","volume":"6","author":"Gomez-Brouchet","year":"2017","journal-title":"Oncoimmunology"},{"key":"2025100308202749000_9.3.e001703.48","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-16-0274"},{"key":"2025100308202749000_9.3.e001703.49","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2017.1331194","article-title":"PD1-positive tumor-infiltrating lymphocytes are associated with poor clinical outcome after pulmonary metastasectomy for colorectal cancer","volume":"6","author":"Kollmann","year":"2017","journal-title":"Oncoimmunology"},{"key":"2025100308202749000_9.3.e001703.50","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.4161\/onci.21680","article-title":"Studying the role of the immune system on the antitumor activity of a hedgehog inhibitor against murine osteosarcoma","volume":"1","author":"Paget","year":"2012","journal-title":"Oncoimmunology"},{"key":"2025100308202749000_9.3.e001703.51","doi-asserted-by":"publisher","DOI":"10.1038\/nm0697-682"},{"key":"2025100308202749000_9.3.e001703.52","article-title":"Oncolytic virus promotes tumor-reactive infiltrating lymphocytes for adoptive cell therapy","author":"Feist","year":"2020","journal-title":"Cancer Gene Ther"},{"key":"2025100308202749000_9.3.e001703.53","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5402\/2011\/168712","article-title":"High expression of complement component 5 (C5) at tumor site associates with superior survival in Ewing's sarcoma family of tumour patients","volume":"2011","author":"Savola","year":"2011","journal-title":"ISRN Oncol"},{"key":"2025100308202749000_9.3.e001703.54","doi-asserted-by":"crossref","first-page":"976","DOI":"10.3390\/cells9040976","article-title":"The osteosarcoma microenvironment: a complex but targetable ecosystem","volume":"9","author":"Corre","year":"2020","journal-title":"Cells"},{"key":"2025100308202749000_9.3.e001703.55","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1613187113"},{"key":"2025100308202749000_9.3.e001703.56","doi-asserted-by":"crossref","first-page":"153303381881607","DOI":"10.1177\/1533033818816076","article-title":"Granulocyte colony-stimulating factor treatment during radiotherapy is associated with survival benefit in patients with lung cancer","volume":"17","author":"Du","year":"2018","journal-title":"Technol Cancer Res Treat"},{"key":"2025100308202749000_9.3.e001703.57","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2012.077040"},{"key":"2025100308202749000_9.3.e001703.58","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2012.069260"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2020-001703","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T15:20:37Z","timestamp":1759504837000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2020-001703"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":58,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2021,3,18]]},"published-print":{"date-parts":[[2021,3]]}},"alternative-id":["10.1136\/jitc-2020-001703"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2020-001703","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3]]}}}